Ovid Therapeutics (OVID) Depreciation & Amortization (CF) (2016 - 2026)

Ovid Therapeutics has reported Depreciation & Amortization (CF) for 11 years, with the latest figure at $35000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 75.18% year-over-year to $35000.0; the trailing twelve-month figure through Mar 2026 stood at $167000.0 (down 72.98% YoY), and the FY2025 full-year result was $273000.0, down 55.46% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $35000.0, up from $17000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $184980.0 in Q4 2022, with the low at $16000.0 in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $117735.6 across 5 years, with a median of $140000.0 in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 224.81% — and 2025, when it tumbled 90.53%.
• Ovid Therapeutics' Depreciation & Amortization (CF) stood at $184980.0 in 2022, then retreated by 24.32% to $140000.0 in 2023, then increased by 14.29% to $160000.0 in 2024, then tumbled by 89.38% to $17000.0 in 2025, then jumped by 105.88% to $35000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $35000.0 (Q1 2026), $17000.0 (Q4 2025), and $16000.0 (Q3 2025), per Business Quant data.